Non-Small Cell Lung Cancer

NSCLC is an early but increasingly interesting setting for WFA.

The strongest reasons are EMT suppression, paclitaxel synergy, and immune checkpoint sensitisation.

Cell data

WFA suppresses TGFβ1 and TNFα-driven EMT in NSCLC cell lines such as A549 and H1299.

At sub-cytotoxic concentrations, it reduces adhesion, migration, and invasion without needing overt cell killing. That makes the anti-metastatic signal especially interesting.

WFA has also shown synergy with paclitaxel in NSCLC models, improving effects on proliferation and invasive behaviour.

Animal data

The most important animal data comes from syngeneic lung cancer work. In that setting, WFA combined with anti-PD-L1 therapy reduced tumour growth more effectively than either agent alone and increased CD8+ T-cell infiltration.

This makes NSCLC the strongest current disease setting for WFA's checkpoint-sensitisation hypothesis.

Human data

There is no NSCLC-specific human efficacy trial yet.

Clinical setting assessment

NSCLC remains early, but the translational logic is strong.

Because checkpoint inhibitors are already part of standard care in many lung cancer settings, WFA fits a clinically recognisable design space. That makes this disease area more interesting than its current evidence volume alone might suggest.

Bottom line

NSCLC is not yet one of the deepest WFA evidence bases, but it may be one of the most strategically important for future combination trials.

Key references

Kim S. H. et al. — EMT suppression and anti-invasive effects in NSCLC models.
https://onlinelibrary.wiley.com/doi/10.1002/mc.22110

Banerjee S. et al. — anti-PD-L1 sensitisation and immune-microenvironment reshaping in syngeneic lung cancer.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10295988/

Access and availability:
Source: MCS Formulas, “Withaferin A Pro Liposomal.”
50 mg WFA per capsule. Available via healthcare professional request.
https://www.mcsformulas.com/vitamins-supplements/withaferin-a-pro-liposomal/ref/14